摘要
本文首次报道对血清AFP＜20ng·ml^(-1)肝癌及肝病患者作甲胎蛋白异质体测定。原发性肝癌组74例，扁豆凝集素（LCA）非结合型AFP（AFP-N-L）_x^-±SD：42.19±28.99％，其中AFP＜20ng·ml^(-1)19例为23.67±35.12％，AFP＜20ng·ml^(-1) 55例48.58±23.73％，前者明显低于后者（p＜0.001）。良性肝病组49例98.14±13.81％，其中AFP＜20ng·ml^(-1)25例95.98±14.45％，AEP＞20ng·ml^(-1) 24例92.3±13.16％，二者无差异。肝癌组明显低于肝病组（P＜0.001）。简略讨论了AFP异质体测定的临床意义。
This is the first time to report the determination of AFP heterogeneity ia patients with serum AFP<20ng.ml-1. The percentage of AFP-N-L was significantly lower in 74 patients with primary hepatic carcinoma (Group PHC, x sd : 42.18 ± 28.89%) than in 49 patients with benign liver disease (Group BLD : 94.18± 13.81% p<0.001) . In Group PHC AFP-N-L percentage was significantly lower in patients with serum AFP<20ng,ml-1 (n = 19, 23.67±35.12%) than ill patients with serum AFP>20ng.ml-1 (n = 55, 48.58 ±23.73%, p<0.001) . in Group BLD AFP-N-L percentage was no difference between 25 patients with serum AFP <20ng.ml-1 and 24 patients with serum AFP>20ng.rnl-1. Briefly discussed the clinical sig-nificance of AFP heterogeneity.
出处
《重庆医药》
CSCD
1989年第4期1-2,共2页
关键词
肝癌
甲胎蛋白
异质体
AFP
AFP heterogeneity primary hepatic carcuiotia affmity electrophoiesis
